[go: up one dir, main page]

WO2009033819A3 - Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids - Google Patents

Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids Download PDF

Info

Publication number
WO2009033819A3
WO2009033819A3 PCT/EP2008/008187 EP2008008187W WO2009033819A3 WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3 EP 2008008187 W EP2008008187 W EP 2008008187W WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3
Authority
WO
WIPO (PCT)
Prior art keywords
ser
asp
pro
combination
disease
Prior art date
Application number
PCT/EP2008/008187
Other languages
French (fr)
Other versions
WO2009033819A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Laboratories Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories Ag filed Critical Mondobiotech Laboratories Ag
Publication of WO2009033819A2 publication Critical patent/WO2009033819A2/en
Publication of WO2009033819A3 publication Critical patent/WO2009033819A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the peptide compounds Arg-Ser-Leu-Gln-Asp-Thr-Glu-Glu-Lys-Ser-Arg-Ser-Phe-Ser-Ala-Ser- Gln-Ala-Asp-Pro-Leu-Ser-Asp-Pro-Asp-Gln-Met-Asn-Glu-Asp-OH and Gln-Arg-Pro- Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008187 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent WO2009033819A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017749.8 2007-09-11
EP07017766.2 2007-09-11
EP07017766 2007-09-11
EP07017749 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033819A2 WO2009033819A2 (en) 2009-03-19
WO2009033819A3 true WO2009033819A3 (en) 2009-11-05

Family

ID=40452600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008187 WO2009033819A2 (en) 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009033819A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2013079487A1 (en) * 2011-11-28 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
MX2016001021A (en) 2013-07-25 2016-08-03 Novartis Ag Bioconjugates of synthetic apelin polypeptides.
CN104436158A (en) * 2013-09-22 2015-03-25 华中科技大学 Application of Apelin-13 to treatment of diabetic nephropathy
CN114099637A (en) * 2021-12-15 2022-03-01 广东省职业病防治院(广东省职业卫生检测中心) Application of Apelin in preparation of medicine for treating silicosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405608A (en) * 1980-08-28 1983-09-20 Novo Industri A/S Novel peptide
EP1116727A1 (en) * 1998-09-25 2001-07-18 Takeda Chemical Industries, Ltd. Peptide derivative
WO2004081198A2 (en) * 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405608A (en) * 1980-08-28 1983-09-20 Novo Industri A/S Novel peptide
EP1116727A1 (en) * 1998-09-25 2001-07-18 Takeda Chemical Industries, Ltd. Peptide derivative
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
WO2004081198A2 (en) * 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
HAN ET AL: "Increased colonic apelin production in rodents with experimental colitis and in humans with IBD", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 142, no. 3, 14 June 2007 (2007-06-14), pages 131 - 137, XP022116452, ISSN: 0167-0115 *
HOLST J J: "Enteroglucagon.", ANNUAL REVIEW OF PHYSIOLOGY 1997, vol. 59, 1997, pages 257 - 271, XP002540448, ISSN: 0066-4278 *
HUI XIE ET AL: "Apelin suppresses apoptosis of human osteoblasts", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, vol. 12, no. 1, 21 November 2006 (2006-11-21), pages 247 - 254, XP019463727, ISSN: 1573-675X *
KASAI A ET AL: "Apelin is a novel angiogenic factor in retinal endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 325, no. 2, 10 December 2004 (2004-12-10), pages 395 - 400, XP004626806, ISSN: 0006-291X *
KLEINZ M J ET AL: "Emerging roles of apelin in biology and medicine", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 107, no. 2, 1 August 2005 (2005-08-01), pages 198 - 211, XP004963619, ISSN: 0163-7258 *
LADEIRAS-LOPES RICARDO ET AL: "The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications.", ARQUIVOS BRASILEIROS DE CARDIOLOGIA MAY 2008, vol. 90, no. 5, May 2008 (2008-05-01), pages 343 - 349, XP002539444, ISSN: 1678-4170 *
LEE D K ET AL: "Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 27, no. 4, 1 April 2006 (2006-04-01), pages 190 - 194, XP025029550, ISSN: 0165-6147, [retrieved on 20060401] *
MASRI B ET AL: "Apelin signalling: a promising pathway from cloning to pharmacology", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 17, no. 4, 1 April 2005 (2005-04-01), pages 415 - 426, XP025337469, ISSN: 0898-6568, [retrieved on 20050401] *
OHNEDA A ET AL: "EFFECT OF GLICENTIN-RELATED PEPTIDES UPON THE SECRETION OF INSULIN AND GLUCAGON IN THE CANINE PANCREAS", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 155, no. 2, 1988, pages 197 - 204, XP002540447, ISSN: 0040-8727 *
SAINT-GENIEZ M ET AL: "Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 110, 1 January 2002 (2002-01-01), pages 183 - 186, XP002992963, ISSN: 0925-4773 *
SORLI S C ET AL: "Therapeutic potential of interfering with apelin signalling", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 11, no. 23-24, 1 December 2006 (2006-12-01), pages 1100 - 1106, XP025027123, ISSN: 1359-6446, [retrieved on 20061201] *
TANG ET AL: "Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 28, no. 3, 7 February 2007 (2007-02-07), pages 708 - 718, XP005877280, ISSN: 0196-9781 *

Also Published As

Publication number Publication date
WO2009033819A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009033797A3 (en) Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
LTPA2017015I1 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
MY161340A (en) Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
UA85471C2 (en) Use of oxycodone for treating visceral pain
PL1951273T3 (en) Use of lactobacillus for treatment of autoimmune diseases
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2012101156A3 (en) Human lactoferrin based peptides having antiinflammatory activity
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2012061390A3 (en) Therapeutic compositions and methods
MX2013003060A (en) Combination therapy for treating hcv infection.
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830656

Country of ref document: EP

Kind code of ref document: A2